The (A) case asks: How should GSK respond to these pressures? The (B) case summarizes GSK’s responses of 2002 and subsequent events. Primary teaching objectives are: 1) To examine an issue of ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...
GSK already has a strong presence in respiratory disease and immunology, two of its core therapeutic areas. The pharmaceutical giant is now teaming up with Flagship Pioneering in an alliance ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...
Daily Maverick on MSN17d
Competition law has again worked to fight a bad drug patent, but we need other solutionsA Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South ...
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech. The recombinant protein vaccine ...
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback